Celularity Inc

CELU

Celularity Inc

CELU

Insider Sentiment (TTM):

Last Purchase:2024-01-12Last Sale:2023-10-05Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:2,156,255Shares Outstanding:25,598,586Institutional Ownership Pct.:8.42%

Earnings Market Reaction:

Filing Date:2026-04-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	6	0	1	0	1	0	0	2	0	0	3	9
Accounts And Other Receivables Net Current	5	7	11	15	14	9	13	14	10	4	3	3
Inventory Net	1	3	4	6	5	4	3	4	6	5	6	5
Prepaid Expense And Other Assets Current	1	1	1	1	1	2	1	1	2	5	4	6
Assets Current	12	11	17	22	21	15	18	23	20	16	18	25
Assets Noncurrent
Property Plant And Equipment Net	56	57	59	60	62	63	65	66	68	71	73	74
Long Term Investments	-	3	-	-	-	-	-	-	-	-	-	-
Goodwill	7	7	7	7	7	7	7	7	7	7	90	90
Intangible Assets Net Excluding Goodwill	8	8	9	9	9	10	10	10	11	12	12	120
Operating Lease Right Of Use Asset	11	11	11	11	11	11	11	11	11	11	13	13
Restricted Cash Noncurrent	10	10	10	10	10	10	10	10	10	15	15	15
Inventory Noncurrent	3	7	7	9	13	13	14	16	17	25	25	25
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	107	114	120	129	133	129	135	144	144	157	246	362
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	26	25	24	23	23	15	14	13	14	13	12	9
Accrued Liabilities And Other Liabilities	33	29	33	25	20	14	10	9	8	10	9	10
Short Term Borrowings	-	-	-	-	-	-	-	-	17	14	17	31
Contract With Customer Liability Current	5	6	4	3	4	4	3	3	3	2	2	2
Asset Acquisition Contingent Consideration Liabili…	-	-	-	-	1	-	-	-	-	-	-	-
Other Liabilities Current	0	-	-	-	-	-	-	-	-	-	-	-
Derivative Liabilities Current	0	-	-	-	-	-	-	-	-	-	-	-
Liabilities Current	81	65	69	59	54	76	68	66	67	85	65	66
Liabilities Noncurrent
Contract With Customer Liability Noncurrent	3	3	3	3	3	3	3	3	3	3	2	2
Business Combination Contingent Consideration Liab…	-	-	-	-	-	2	2	2	2	2	2	87
Asset Acquisition Contingent Consideration Liabili…	-	1	1	1	1	-	-	-	2	-	-	-
Business Combination Contingent Consideration Liab…	1	-	-	-	1	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	27	27	27	27	27	26	26	26	26	26	28	28
Long Term Debt	-	-	-	-	-	-	-	-	-	-	17	5
Deferred Income Tax Liabilities Net	0	0	0	0	0	0	0	0	0	0	0	0
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	145	134	146	134	124	112	108	113	103	127	128	207
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	953	947	919	914	909	904	898	895	883	879	874	862
Retained Earnings Accumulated Deficit	-991	-967	-944	-920	-900	-886	-870	-864	-842	-851	-757	-710
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-0	-	-0	-0	-	-	-	2	2	3
Stockholders Equity	-38	-20	-25	-6	9	17	28	31	41	30	119	156
Liabilities And Stockholders Equity	107	114	120	129	133	129	135	144	144	157	246	362
Shortterm Debt Fair Value	-	-	-	-	2	4	3	2	17	14	17	31
Allowance For Doubtful Accounts Receivable Current	8	6	6	6	6	6	6	6	6	2	2	2
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Debt Default Shortterm Debt Amount	-	-	-	-	-	-	-	-	17	17	17	32
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	2	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	2	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	730	730	730	730	730	730	730	730	730	730	730	730
Common Stock Shares Issued	29	28	25	24	23	22	22	22	19	19	18	17
Shares Outstanding	29	28	25	24	23	22	22	22	19	19	18	17

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	-	-	-	-43.65%	-49.75%	-60.66%	27.74%	-21.94%	-21.29%	-6.85%	-19.49%	-16.49%
2024	27.70%	-15.11%	-17.27%	-33.98%	-27.51%	-19.09%	-5.08%	5.93%	-28.81%	27.11%	11.45%	78.31%
2023	20.00%	-26.22%	-52.59%	1.92%	-30.35%	-25.24%	22.06%	65.12%	84.70%	5.72%	-0.33%	-16.05%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	0.15	0.16	0.25	0.38	0.38	0.19	0.26	0.35	0.29	0.19	0.28	0.38
Quick Ratio	0.13	0.10	0.17	0.26	0.27	0.12	0.21	0.27	0.18	0.08	0.12	0.21
Working Capital	-68.44M	-54.72M	-51.96M	-36.61M	-33.12M	-61.67M	-50.17M	-43.19M	-47.51M	-68.13M	-46.94M	-41.45M
Leverage & Debt
Debt to Equity	-3.82	-6.69	-5.72	-24.41	14.01	6.46	3.87	3.60	2.51	4.20	1.08	1.33
Debt Ratio	1.35	1.18	1.21	1.04	0.93	0.87	0.79	0.78	0.72	0.81	0.52	0.57
Efficiency & Turnover
Asset Turnover TTM	0.22	0.33	0.35	0.37	0.39	0.34	0.22	0.13	0.08	0.05	0.04	0.04
Per Share Metrics
Diluted EPS TTM	-3.59	-3.06	-3.07	-2.36	-2.64	-1.60	-5.16	-7.20	-11.02	-9.63	-4.69	0.84
Free Cash Flow Per Share TTM	-0.52	-0.25	-0.11	-0.22	-0.30	-0.59	-0.98	-1.35	-2.23	-3.46	-5.43	-7.89
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	24.39%	50.61%	55.10%	66.83%	72.36%	64.20%	60.24%	53.30%	29.66%	52.33%	71.86%	75.70%
Operating Profit Margin TTM	-230.92%	-119.60%	-105.76%	-81.37%	-70.75%	-32.70%	-242.43%	-405.15%	-844.44%	-1,272.09%	-624.34%	-299.57%
Net Profit Margin TTM	-345.76%	-198.75%	-165.22%	-109.16%	-106.77%	-72.73%	-264.30%	-460.34%	-862.04%	-1,226.72%	-546.56%	81.64%
Growth Metrics
Net Revenue Growth (1Y)	-51.03%	-15.81%	4.45%	52.06%	138.11%	225.94%	182.02%	109.81%	26.68%	-20.93%	-39.91%	-35.09%
Net Income Growth (1Y)	58.57%	130.07%	-34.71%	-63.94%	-70.51%	-80.68%	36.38%	-1,283.03%	-1,483.14%	1,170.19%	-368.12%	-116.01%
EPS Growth (1Y)	35.60%	91.90%	-40.61%	-67.15%	-76.00%	-83.44%	10.20%	-957.25%	-1,186.34%	862.35%	-312.83%	-113.44%
Valuation Metrics
P/E TTM	-0.31	-0.68	-0.64	-0.73	-0.79	-1.86	-0.61	-0.73	-0.22	-0.23	-1.14	7.39
P/B TTM	-0.75	-2.71	-1.85	-7.39	5.15	3.78	2.46	3.59	1.07	1.38	0.79	0.62
P/S TTM	1.07	1.34	1.06	0.80	0.84	1.35	1.60	3.35	1.93	2.83	6.22	6.03
Market Cap	28.41M	54.54M	47.08M	40.71M	45.53M	65.27M	68.39M	112.14M	44.00M	41.81M	94.11M	96.33M
Enterprise Value	12.04M	44.28M	36.14M	30.40M	34.56M	54.94M	57.84M	100.19M	51.06M	40.71M	110.04M	108.66M
Calculated Values
Free Cash Flow TTM	-13.25M	-6.65M	-2.63M	-5.11M	-6.56M	-12.99M	-21.39M	-28.97M	-39.73M	-65.18M	-95.91M	-122.61M
Net Debt	-16.37M	-10.26M	-10.94M	-10.30M	-10.98M	-10.33M	-10.55M	-11.95M	7.06M	-1.09M	15.93M	12.33M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-01-12Purchase

Owner: Genting, Berhad, Dragasac…

Title: -

Shares: 21,410,983

Price/Share: $0.25

Value: $5,352,745.75

Shares Owned: 51,473,762

Relationship: TenPercentOwner

Ownership: Indirect

2023-10-05Purchase

Owner: Hariri, Robert J

Title: Chief Executive Officer

Shares: 9,357,585

Price/Share: $0.16

Value: $1,497,213.60

Shares Owned: 28,570,434

Relationship: Director,Officer

Ownership: Direct

2023-10-05Sale

Owner: Sorrento, Therapeutics, I…

Title: -

Shares: 6,307,158

Price/Share: -

Value: -

Shares Owned: 5,050,427

Relationship: TenPercentOwner

Ownership: Direct

2022-11-30Purchase

Owner: Hariri, Robert J

Title: Chief Executive Officer

Shares: 10,000

Price/Share: $1.72

Value: $17,200.00

Shares Owned: 8,074,996

Relationship: Director,Officer

Ownership: Direct

2022-11-29Purchase

Owner: Hariri, Robert J

Title: Chief Executive Officer

Shares: 40,000

Price/Share: $1.71

Value: $68,400.00

Shares Owned: 8,064,996

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-01-12	Genting, Berhad, Dragasac…	TenPercentOwner	-	Indirect	Purchase	21,410,983	0.25	$5,352,745.75	51,473,762	4
2023-10-05	Hariri, Robert J	Director,Officer	Chief Executive Officer	Direct	Purchase	9,357,585	0.16	$1,497,213.60	28,570,434	4
2023-10-05	Sorrento, Therapeutics, I…	TenPercentOwner	-	Direct	Sale	6,307,158	-	-	5,050,427	4
2022-11-30	Hariri, Robert J	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	1.72	$17,200.00	8,074,996	4
2022-11-29	Hariri, Robert J	Director,Officer	Chief Executive Officer	Direct	Purchase	40,000	1.71	$68,400.00	8,064,996	4
2022-11-28	Hariri, Robert J	Director,Officer	Chief Executive Officer	Direct	Purchase	40,000	1.74	$69,600.00	8,024,996	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

8.42%

Inst. Shares: 2,156,255

Shares Outstanding: 25,598,586

2025-12-31

8.65%

Inst. Shares: 2,213,504

Shares Outstanding: 25,598,586

2025-09-30

8.59%

Inst. Shares: 2,262,329

Shares Outstanding: 26,347,818

2025-06-30

8.11%

Inst. Shares: 1,947,907

Shares Outstanding: 24,020,193

2025-03-31

8.29%

Inst. Shares: 1,950,441

Shares Outstanding: 23,530,877

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	2,156,255	25,598,586	8.42%
2025-12-31	2,213,504	25,598,586	8.65%
2025-09-30	2,262,329	26,347,818	8.59%
2025-06-30	1,947,907	24,020,193	8.11%
2025-03-31	1,950,441	23,530,877	8.29%
2024-12-31	1,831,950	21,890,518	8.37%
2024-09-30	961,046	21,976,339	4.37%
2024-06-30	939,334	21,849,759	4.30%
2024-03-31	786,304	21,440,980	3.67%
2023-12-31	7,393,745	17,813,044	41.51%
2023-09-30	35,738,730	18,831,713	189.78%
2023-06-30	34,804,209	17,656,390	197.12%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Celularity Inc (CELU) — SEC Financial Statements & Analysis

Celularity Inc (CELU) is a pharmaceutical preparations company, incorporated in DE. Celularity Inc trades on Nasdaq as: CELU, CELUW. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Celularity Inc reported a -51.03% year-over-year revenue growth, a Gross Profit Margin of 24.39% (TTM), a Debt-to-Equity ratio of -3.82x, a Price-to-Sales (P/S) ratio of 1.07x (TTM), a Price-to-Book (P/B) ratio of -0.75x (TTM), at a market cap of $28.41M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -51.03%
Gross Profit Margin TTM: 24.39%
Debt To Equity: -3.82x
P/S TTM: 1.07x
P/B TTM: -0.75x
Market Cap: $28.41M

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Celularity Inc in?

Celularity Inc (CELU) operates in the Pharmaceutical Preparations industry.

What is CELU's market cap?

Celularity Inc (CELU) has a market capitalization of $28.41M as of 2025-12-31.

What exchange does CELU trade on?

Celularity Inc (CELU) trades on the Nasdaq.

Where is Celularity Inc incorporated?

Celularity Inc is incorporated in DE.

Celularity Inc

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Celularity Inc (CELU) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Celularity Inc (CELU) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.